Novel formulation for oral administration, comprising 1-(5-(2,4-difluorophenyl)-1-( (3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine

IR114330BUndetermined Publication Date: 2026-08-23DAEWOONG PHARM CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
IR140250140003002021
Authority / Receiving Office
IR · IR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2023-06-17
Publication Date
2026-08-23
Estimated Expiration
2043-06-17
Patent Text Reader
Need to check novelty before this filing date? Find Prior Art
No text content released.